CAS-89-57-6

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

93 API Suppliers, 53 USDMF, 34 CEP/COS, 13 JDMF, 14 EU WC, 10 KDMF, 45 NDC API, 43 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

INTERMEDIATES

7 Intermediates Suppliers

7 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

442 FDF Dossiers, 41 FDA Orange Book, 293 Europe, 17 Canada, 40 Australia, 13 South Africa, 38 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

ENEMA;RECTAL - 4GM/60ML, CAPSULE, EXTENDED RELEASE;ORAL - 250MG, CAPSULE, EXTENDED RELEASE;ORAL - 500MG, CAPSULE, DELAYED RELEASE;ORAL - 400MG, SUPPOSITORY;RECTAL - 1GM, TABLET, DELAYED RELEASE;ORAL - 800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - 1.2GM, CAPSULE, EXTENDED RELEASE;ORAL - 375MG

RELATED EXCIPIENT COMPANIES

3 Evonik, 3 Rochem International Inc, 1 SPI Pharma, 2 Seqens, 11 DKSH, 1 Pharm-RX Chemical, 3 Faran Shimi Pharmaceutical, 5 Boai NKY Pharmaceuticals Ltd, 10 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 2 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 31 BASF, 15 Corel Pharma Chem, 5 DFE Pharma, 3 Doshion Polyscience, 1 Finar, 9 Gangwal Chemicals, 13 Ideal Cures Pvt Ltd, 1 Ingredion Pharma Solutions, 30 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 2 Lubrizol Life Science Health, 17 Microlex e.U, 2 Nomisma Healthcare, 3 Novo Excipients, 4 Pharmatrans-Sanaq, 3 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 13 Roquette, 6 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 11 Sigachi Industries, 3 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem, 2 Vertellus

EXCIPIENTS BY APPLICATIONS

67 Coating Systems & Additives, 59 Fillers, Diluents & Binders, 43 Controlled & Modified Release, 37 Thickeners and Stabilizers, 31 Direct Compression, 28 Disintegrants & Superdisintegrants, 25 Solubilizers, 22 Granulation, 18 Lubricants & Glidants, 15 Topical, 14 Film Formers & Plasticizers, 13 Co-Processed Excipients, 11 Taste Masking, 9 Empty Capsules, 8 Rheology Modifiers, 7 Chewable & Orodispersible Aids, 6 Parenteral, 5 API Stability Enhancers, 4 Emulsifying Agents, 4 Vegetarian Capsules, 4 Coloring Agents, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

4 DATA COMPILATION #PharmaFlow, 66 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

9 US Medicaid Prescriptions, 200 Finished Drug Prices, 35 Annual Reports

MARKET PLACE

22 APIs, 14 FDF Dossiers

PATENTS & EXCLUSIVITIES

4 US Patents, 13 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 EDQM, 1 USP, 15 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 21252 / DOSAGE - SUPPOSITORY;RECTAL - 1GM

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
MESALAMINE(UNII: 4Q81I59GXC) (MESALAMINE - UNII:4Q81I59GXC)	MESALAMINE	1000mg

Inactive Ingredients

Ingredient Name	Amneal Pharmaceuticals NY LLC	Mckesson Rxpak Inc	Mylan Pharmaceuticals Inc.	Sandoz Inc
FAT, HARD(8334LX7S21)
HARD FAT(8334LX7S21)

Drug Product Composition: CAS-89-57-6

CAS-89-57-6

CAS-89-57-6

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

93 API Suppliers

53 USDMF

34 CEP/COS

13 JDMF

14 EU WC

10 KDMF

45 NDC API

43 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

4 Drugs in Development

INTERMEDIATES

7 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

442 FDF Dossiers

41 FDA Orange Book

293 Europe

17 Canada

40 Australia

13 South Africa

38 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

ENEMA;RECTAL - 4GM/60ML

CAPSULE, EXTENDED RELEASE;ORAL - 250MG

CAPSULE, EXTENDED RELEASE;ORAL - 500MG

CAPSULE, DELAYED RELEASE;ORAL - 400MG

SUPPOSITORY;RECTAL - 1GM

TABLET, DELAYED RELEASE;ORAL - 800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - 1.2GM

CAPSULE, EXTENDED RELEASE;ORAL - 375MG

RELATED EXCIPIENT COMPANIES

3 Evonik

3 Rochem International Inc

1 SPI Pharma

2 Seqens

11 DKSH

1 Pharm-RX Chemical

3 Faran Shimi Pharmaceutical

5 Boai NKY Pharmaceuticals Ltd

10 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

4 ACG Worldwide

3 Actylis

1 Aeon Procare

2 Alcedo Pharmachem

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

31 BASF

15 Corel Pharma Chem

5 DFE Pharma

3 Doshion Polyscience

1 Finar

9 Gangwal Chemicals

13 Ideal Cures Pvt Ltd

1 Ingredion Pharma Solutions

30 Kerry

4 Kima Chemical

6 Lonza Capsugel

2 Lubrizol Life Science Health

17 Microlex e.U

2 Nomisma Healthcare

3 Novo Excipients

4 Pharmatrans-Sanaq

3 Pluviaendo

3 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

13 Roquette

6 Seppic

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

11 Sigachi Industries

3 The Dow Chemical Company

1 Ulanqab Kema New Material

TABLET, DELAYED RELEASE;ORAL - 800MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons